Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
394 stopped studies mapped to Hepatocellular Carcinoma and descendants · 93% state a reason
Over the 394 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04212221 | MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in… | Phase 1 / Phase 2 | terminated | Dec 26, 2019 | Zai Lab (Shanghai) Co., Ltd. | Due to the rapid shifting of liver cancer disease landscape and the company's adjustment of… | Sponsor / business decision |
| NCT02314052 | Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular… | Phase 1 / Phase 2 | terminated | Dec 10, 2014 | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | Sponsor decision | Sponsor / business decision |
| NCT02649868 | LC Bead LUMI Radio-Opaque Embolic Beads to Detect and Characterize the Vascularity of… | N/A | terminated | Jan 8, 2016 | National Institutes of Health Clinical Center (CC) | unavailability of study device | Other (stated, no rule matched) |
| NCT04315883 | Yttrium-90 (TARE-Y90) in Children, Adolescents, and Young Adults With Liver Tumors | — | terminated | Mar 20, 2020 | Nemours Children's Clinic | PI left organization and discontinued study | Investigator |
| NCT04541173 | Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable… | Phase 2 | terminated | Sep 9, 2020 | Aiwu Ruth He, MD | Due to slow accrual. | Enrollment / accrual |
| NCT05061537 | Study of PF-07263689 in Participants With Selected Advanced Solid Tumors | Phase 1 | terminated | Sep 29, 2021 | Pfizer | The study was terminated by the Sponsor due to business decision and not due to any safety concerns… | Safety / toxicity |
| NCT03958669 | Fingerprint Characterization Tyrosine Kinase Inhibitors in Advanced HCC(e:Med-HCC-2) | — | terminated | May 22, 2019 | University Hospital Tuebingen | Slow recruitment due to COVID-19 pandemic and several newly approved treatment options | COVID-19 / pandemic |
| NCT02762266 | Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or… | Phase 3 | terminated | May 4, 2016 | Stanford University | Business decision - funding | Funding |
| NCT05292443 | Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated… | — | withdrawn | Mar 23, 2022 | Geneplus-Beijing Co. Ltd. | No participants were enrolled | Enrollment / accrual |
| NCT03812562 | Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical… | Early Phase 1 | terminated | Jan 23, 2019 | Northwestern University | Lack of funding | Funding |
| NCT03422679 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and… | Phase 1 / Phase 2 | terminated | Feb 6, 2018 | Cellestia Biotech AG | business reason | Sponsor / business decision |
| NCT04244552 | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | Phase 1 | terminated | Jan 28, 2020 | Atreca, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT04187872 | LITT and Pembrolizumab in Recurrent Brain Metastasis(TORCH) | Phase 1 | terminated | Dec 5, 2019 | University of Florida | Sponsor terminated | Other (stated, no rule matched) |
| NCT02802124 | Carbon Ion Radiotherapy for the Treatment of Chinese Hepatocellular Carcinoma | N/A | terminated | Jun 16, 2016 | Shanghai Proton and Heavy Ion Center | For tumor locates away from GI the planned enrolled patient had been completed, but for tumor… | Enrollment / accrual |
| NCT05184283 | Utilization of MAsS in Patients Undergoing LT for HCC | — | terminated | Jan 11, 2022 | Columbia University | Discontinued by Amra Medical due to funding. | Funding |
| NCT03867370 | Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable… | Phase 1 / Phase 2 | terminated | Mar 8, 2019 | Shanghai Junshi Bioscience Co., Ltd. | Enrollment is over, the study was completed | Enrollment / accrual |
| NCT05641922 | Safety and Effectiveness of BioTraceIO 360 for Planning, Monitoring and Assessment of…(PANORAMA2) | N/A | withdrawn | Dec 8, 2022 | Techsomed Medical Technologies LTD | Withdrawn by Sponsor | Other (stated, no rule matched) |
| NCT01690715 | Prognostic Value Related to the Presence of Thrombosis or Portal Vein Invasion in…(HSL2012-06) | — | terminated | Sep 24, 2012 | Hospital Sirio-Libanes | There was recruted subject | Other (stated, no rule matched) |
| NCT05111314 | Comparison of Hepatic Intraarterial Versus Systemic Intravenous 68Ga-PSMA PET/CT for… | Early Phase 1 | withdrawn | Nov 8, 2021 | Mayo Clinic | PI requested | Other (stated, no rule matched) |
| NCT04235660 | Y90 Radiation Segmentectomy vs SBRT for HCC(SBRT vs Y90) | N/A | terminated | Jan 22, 2020 | Indiana University | unable to recruit. terminated due to futility | Efficacy / futility |
| NCT02847468 | Multimetabolic 18F-Fluorodeoxyglucose (FDG) and 18F-Fluorocholine (FCH) Positron Emission…(PREMETHEP) | N/A | terminated | Jul 28, 2016 | Centre Georges Francois Leclerc | Insufficient recruitment | Enrollment / accrual |
| NCT04428437 | Safety and Efficacy of Lenvatinib in Subjects With HCC Progression After First Line… | — | terminated | Jun 11, 2020 | Humanity & Health Medical Group Limited | The sponsor withdrawed the sponsorship to the study. | Other (stated, no rule matched) |
| NCT04106167 | Long-term, Non-interventional, Observational Study Following Treatment With Fate… | — | terminated | Sep 26, 2019 | Fate Therapeutics | This study was terminated by the Sponsor. | Other (stated, no rule matched) |
| NCT05109052 | Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating… | Phase 1 / Phase 2 | withdrawn | Nov 5, 2021 | University of Rochester | no accrual of eligible participants | Enrollment / accrual |
| NCT03970616 | A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced…(DEDUCTIVE) | Phase 1 / Phase 2 | terminated | May 31, 2019 | AVEO Pharmaceuticals, Inc. | The study was terminated due to regulatory approval of newer therapeutic options and slower than… | Enrollment / accrual |
| NCT03722498 | Phase Ⅱ Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACE | Phase 2 | withdrawn | Oct 29, 2018 | Sun Yat-sen University | No patients join | Other (stated, no rule matched) |
| NCT03591965 | Dual TORC1/TORC2 Inhibitor ATG-008 (CC-223) in HBV Positive Advanced Hepatocellular… | Phase 2 | terminated | Jul 19, 2018 | Antengene Therapeutics Limited | Based on the adjustment of clinical research and development strategy，sponsor decided to terminate… | Sponsor / business decision |
| NCT05564338 | Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus… | Phase 3 | withdrawn | Oct 3, 2022 | BeiGene | Study has voluntarily discontinued due to a change in the company-level development strategy and is… | Safety / toxicity |
| NCT05886257 | Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T | Phase 2 | withdrawn | Jun 2, 2023 | Shi Ming | Protocol adjustment | Other (stated, no rule matched) |
| NCT05375604 | A Study of exoASO-STAT6 (CDK-004) in Patients With Advanced Hepatocellular Carcinoma… | Phase 1 | terminated | May 16, 2022 | Codiak BioSciences | Company Bankruptcy | Sponsor / business decision |
| NCT05039736 | A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR… | Phase 2 | withdrawn | Sep 10, 2021 | M.D. Anderson Cancer Center | 0 participants accrued | Enrollment / accrual |
| NCT02174575 | Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery | Phase 4 | withdrawn | Jun 25, 2014 | Tokyo Medical and Dental University | I retired my post before enrollment | Enrollment / accrual |
| NCT03662841 | Ablative Chemoembolization for Unresectable and Large Hepatocellular Carcinoma | N/A | terminated | Sep 10, 2018 | Chinese University of Hong Kong | poor patient accrual | Enrollment / accrual |
| NCT03808766 | A Study on the Angioarchitecture of Hepatocellular Carcinoma | N/A | terminated | Jan 18, 2019 | Chinese University of Hong Kong | Poor patient accrual | Enrollment / accrual |
| NCT05249569 | Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma | Phase 2 | terminated | Feb 21, 2022 | University of Texas Southwestern Medical Center | Sponsor pulled support for one of the study drugs. | Other (stated, no rule matched) |
| NCT04150874 | Contrast-Enhanced Ultrasound for the Evaluation of Changes in Tumor Blood Flow… | Early Phase 1 | terminated | Nov 5, 2019 | H. Lee Moffitt Cancer Center and Research Institute | Slow Accrual | Enrollment / accrual |
| NCT04442581 | Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer | Phase 2 | terminated | Jun 22, 2020 | University of Washington | Terminated due to slow accrual | Enrollment / accrual |
| NCT04777708 | BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer | Early Phase 1 | terminated | Mar 2, 2021 | Jonsson Comprehensive Cancer Center | Withdrawn by sponsor | Other (stated, no rule matched) |
| NCT05157451 | Y-90 Versus SBRT for Inoperable HCC | Phase 2 | withdrawn | Dec 15, 2021 | OHSU Knight Cancer Institute | Not feasible at this time. | Other (stated, no rule matched) |
| NCT04635527 | A Study on the Safety and Effectiveness of IBI318 Combined With Conventional TACE (cTACE)… | Phase 1 | terminated | Nov 19, 2020 | Innovent Biologics (Suzhou) Co. Ltd. | Due to the company's development strategy adjustment ，Innovent Bioligics decided not to continue… | Sponsor / business decision |
| NCT04649671 | The Effect of Mobile Health-based Exercise on Hepatocellular Carcinoma Patients With… | N/A | terminated | Dec 2, 2020 | Samsung Medical Center | Difficulty in recruitment and deficit of research fund | Enrollment / accrual |
| NCT02899325 | FDGal PET/CT to Detect Hepatocellular Carcinoma | — | withdrawn | Sep 14, 2016 | British Columbia Cancer Agency | PIs will not pursue trial due to staff and time constraints | Other (stated, no rule matched) |
| NCT04965714 | Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer | Phase 2 | withdrawn | Jul 16, 2021 | M.D. Anderson Cancer Center | 0 patient accrual | Enrollment / accrual |
| NCT05592197 | Safety and Efficacy of Radiation Plus TACE and Lenvatinib in Advanced HCC With PVTT | N/A | withdrawn | Oct 24, 2022 | Sun Yat-sen University | This is a sub-study of another one. | Other (stated, no rule matched) |
| NCT03236649 | The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced… | Phase 3 | terminated | Aug 2, 2017 | Beijing Shenogen Biomedical Co., Ltd | Because the clinical development plan has been changed. | Other (stated, no rule matched) |
| NCT04077372 | Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal… | N/A | terminated | Sep 4, 2019 | Stanford University | Covid-19 | COVID-19 / pandemic |
| NCT05628545 | Adoptive Treatment of Advanced Hepatocellular Carcinoma With Allogeneic γδ-T Cells | Phase 1 / Phase 2 | withdrawn | Nov 28, 2022 | Guangdong GD Kongming Biotech LLC | COVID1-19 pandemic | COVID-19 / pandemic |
| NCT03582618 | CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma | Phase 2 | terminated | Jul 11, 2018 | TaiRx, Inc. | The study has been terminated due to slow enrollment | Enrollment / accrual |
| NCT01433016 | Detection of Hepatocellular Carcinoma (HCC) With Octanoate Breath ID Test Compared to MRI(OBT for HCC) | Phase 2 | terminated | Sep 13, 2011 | Meridian Bioscience, Inc. | Due to budgetary issues, the company has decided to focus on other applications at this stage. | Funding |
| NCT01381211 | Transarterial RAdioembolization Versus ChemoEmbolization for the Treatment of…(TRACE) | Phase 2 | terminated | Jun 27, 2011 | University Hospital, Ghent | based on interim analysis results | Efficacy / futility |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jul 23, 2024source: clinicaltrials